European CHMP Issues Positive Opinion for repeated intermittent use of Esmya® 5 mg in the long term management of Uterine Fibroids

Gedeon Richter Plc. announces that the CHMP of the EMA has adopted a positive opinion on the company’s application to extend the indication of Esmya® 5 mg tablets (ulipristal acetate) to the long term repeated intermittent treatment of moderate to severe symptoms of uterine fibroids.